ADA-Predictor: HLA-DQA1*05 doubles anti-drug antibody risk in biologic therapy — executable Monte Carlo risk stratification

Anti-drug antibodies cause secondary failure in 10-60% of biologic-treated patients. ADA-Predictor quantifies immunogenicity risk across 10 domains including HLA-DQA1*05 carrier status (OR 1.90, PANTS study Kennedy Lancet GH 2019 DOI:10.1016/S2468-1253(19)30015-3), concomitant methotrexate, biologic type, and prior failure. Monte Carlo (1000 iterations) provides uncertainty bands. Demo: adalimumab without MTX = 72% ADA risk; with MTX = 41%. Not validated in clinical cohort. Authors: Zamora-Tehozol EA (ORCID:0000-0002-7888-3961), DNAI.